About: Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

article

Attributes	Values
rdf:type	Item
description	article (en) wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2014 (uk) article scientifique publié en 2014 (fr) im Dezember 2014 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q56972032-916A82C0-8F1A-408B-ADB8-0C98A75EAA1B
publication date	2014-09-20 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56972032-C5B5613D-BB90-41A4-B209-E68F56E7419B
language of work or name	English
exact match	wds:Q56972032-416A56A4-A525-45FB-9E95-6A13147B603F
exact match	https://scigraph.springernature.com/pub.10.1007/s00228-014-1755-1
cites work	wds:Q56972032-11D7963B-42EA-4657-8ED4-C2A2B6F1A8E2 wds:Q56972032-18D341FC-296D-453E-A5BC-07E378412970 wds:Q56972032-1D90FD80-C91E-44C0-BFC4-6BEE2D107DE8 wds:Q56972032-280CA0D8-B9AF-4430-A01F-4F01C24EB847 wds:Q56972032-2A3FD196-EFF4-4B12-98AF-68B04A1465EE wds:Q56972032-326E9C6A-60A1-487D-BFBB-1F66A69524B3 wds:Q56972032-3373A87C-B0AF-4490-9910-78470D8340E1 wds:Q56972032-43F2E47B-D5D2-4806-8CF8-E40DB294FB47 wds:Q56972032-4AB35B8A-644F-4E6D-8E39-D23F7922486C wds:Q56972032-50055EC6-C2DB-411D-8225-4CC2BB3A6C09 wds:Q56972032-569BA7EB-8DC9-4459-A620-1284091BED3C wds:Q56972032-61706459-F880-4881-9738-F6599CD37664 wds:Q56972032-6591DCAD-1071-46FD-81EE-F9195083AB61 wds:Q56972032-89E1BE9C-5F97-4D1F-B0AB-ED717BCDE7AD wds:Q56972032-9086CA98-E953-4C14-A08C-AA4BA71CACFD wds:Q56972032-B9DC8C67-24BC-4792-A66A-C0FD82250695 wds:Q56972032-C6CF6A40-420F-4388-9CE9-2743961C8CE3 wds:Q56972032-EA39787E-03DB-4974-916F-41BD0070120A wds:Q56972032-F2D50856-0E80-444F-BCC3-B31907430AD7 wds:Q56972032-F2D9753F-E5BB-4D5A-AC89-44EF49857964 wds:Q56972032-F505119A-80B0-42DB-B294-3780F8B293FA wds:Q56972032-FB1FAE53-88E9-4835-99CA-DED5620270ED wds:Q56972032-FBCA01C4-6BC5-4DE4-9096-F9D42EA7C764
cites work	Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard Ranibizumab and bevacizumab for neovascular age-related macular degeneration Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Aflibercept in wet AMD: specific role and optimal use. Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration? The MANTA 1-year results: the anti-VEGF debate continues
author name string	wds:Q56972032-172BBC9E-ED3F-4205-9AA5-312A73FE29FB wds:Q56972032-34775963-3349-4461-9AFE-48B469DF802A wds:Q56972032-52456201-EB55-4B04-97D3-4ED67B879CEE wds:Q56972032-670BF484-A213-4959-802C-05C19A341785 wds:Q56972032-AEE4556B-03AE-44C9-9FBD-1EE47CC00D06 wds:Q56972032-CA9AB67F-EE9B-4D1E-8308-5A767E256702 wds:Q56972032-CBF1B05D-4BB6-46E0-8182-283FEC2A8FED wds:Q56972032-CD37D0FE-AF23-43DC-BD63-21D8720F4217 wds:Q56972032-E8A3BCC5-2880-4182-B201-B1AB8E602B9B wds:Q56972032-F4C290A8-1D14-42F6-8C5D-30DC42D094EE
author name string	C Biagi M Melis M Donati V Conti A Covezzoli N Montanaro A Vaccheri R Amato E Buccellato L Pazzi
rdfs:label	Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions (en) Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions (nl)
skos:prefLabel	Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions (en) Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions (nl)
name	Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions (en) Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions (nl)
author	wds:Q56972032-65C33F66-589E-410D-94C7-169923CA9DB3 wds:Q56972032-CB1A9656-9C9D-4EE8-9C97-7634AA420943
author	Mauro Venegoni Domenico Motola
title	wds:Q56972032-57F75393-681D-4F2F-9C76-9F973474F498
title	Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions (en)
page(s)	wds:Q56972032-A72D7DFD-A721-4243-B7DD-C1D3973E15E9
page(s)	1505-1512
instance of	wds:Q56972032-1B78A4A3-AB67-4D95-8C20-2C771C350FB4
instance of	scholarly article
main subject	wds:Q56972032-3AD5A5A7-3365-4E4B-90A3-2C96D3FF5E08 wds:Q56972032-64B0FBF3-DE69-4704-995F-A2F719DB3847
main subject	bevacizumab World Health Organization
PubMed ID	wds:Q56972032-EB84C775-74AE-4F69-8342-F3417E9EACCC
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/25234795

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software